No Sarge you are the constant presence on this board spreading misinformation and disinformation.
Why you continue 24/7 to devote your time to this is astounding.
Starpharma presented the data demonstrating the superiority of their DEP Irinotecan combination cancer drug over Onivyde at the International Conference on Molecular Targets and Cancer Therapeutics. This conference was co-hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC). The event took place in Boston, US, from 11 to 15 October 20231. At this conference, Starpharma showcased their DEP Irinotecan in combination with leading anti-cancer therapies, including immuno-oncology (IO) agents, in colorectal cancer (CRC) models.
https://www.starpharma.com/assets/asxannouncements/230927%20DEP%C2%AE%20irinotecan%20combination%20data%20presentation%20-%20Final.pdf
https://www.starpharma.com/news/story/dep-irinotecan-combination-data-to-be-presented-at-international-oncology-conference-asx-announcement
No Sarge you are the constant presence on this board spreading...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
